Elodie Gautier‐Veyret

Author

Also Known As

E Gautier‐Veyret, E. Gautier-Veyret, E. Gautier-veyret, Elodie Gautier, Elodie Gautier-Veyret, Elodie Gautier‐Veyret, Gautier-Veyret, Elodie

Publications

942

Citations

H-Index

Concepts

All Affiliations

Université Grenoble Alpes Inserm Centre Hospitalier Universitaire de Grenoble Centre National de la Recherche Scientifique Techniques of Informatics and Microelectronics for Integrated Systems Architecture

About

Elodie Gautier‐Veyret is an author at Université Grenoble Alpes specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	391
2	Health Sciences	3	3	145
3	Allergy	1	1	24
4	Blood Transplantation	1	1	64
5	Epidemiology	1	1	25

Elodie Gautier‐Veyret

Publications

593

Citations

H-Index

Page 1

	Year	Citations
Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels Elodie Gautier‐Veyret, Xavier Fonrose, Julia Tonini, Antimicrobial Agents and Chemotherapy Trough ConcentrationsTransplantation MedicinePharmacotherapyLaboratory HematologyAbstract Voriconazole	2015	64
A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease Théo Willeman, Jean‐François Jourdil, Elodie Gautier‐Veyret, Analytica Chimica Acta Autoimmune DiseaseTherapeutic Monoclonal AntibodiesBioanalysisImmunologyGastroenterology	2019	64
Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis Elodie Gautier‐Veyret, Claire Arnaud, Magnus Bäck, European Respiratory Journal Vascular DiseaseLipid PeroxidationIntermittent Hypoxia ExposureRedox BiologyOxidative Stress	2012	54
Inflammation is a potential risk factor of voriconazole overdose in hematological patients Elodie Gautier‐Veyret, Aurélie Truffot, Sébastien Bailly, Fundamental and Clinical Pharmacology	2018	39
Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods? Jean‐François Jourdil, Dorothée Lebert, Elodie Gautier‐Veyret, Analytical and Bioanalytical Chemistry Translational MedicineGas ChromatographyMedicineBioanalysisImmunology	2016	35
Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates Florian Simon, Elodie Gautier‐Veyret, Aurélie Truffot, Pharmaceutical Research InflammationAnti-inflammatoryPharmacokinetic ModelingPhysiologically-based Pharmacokinetic ModelingMedicine	2021	32
Pharmacogenetics may Influence the Impact of Inflammation on Voriconazole Trough Concentrations Elodie Gautier‐Veyret, Sébastien Bailly, Xavier Fonrose, Pharmacogenomics ImmunologyGenetic ScorePharmacotherapyVoriconazole CminDrug Resistance	2017	27
Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry Jean‐François Jourdil, Benjamin Némoz, Elodie Gautier‐Veyret, Therapeutic Drug Monitoring	2018	26
Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated Elodie Gautier‐Veyret, Anne Thiebaut‐Bertrand, Matthieu Roustit, British Journal of Clinical Pharmacology	2020	26
Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data Léa Bolcato, Charles Khouri, Anette Veringa, Journal of Clinical Medicine Metabolomic ProfilingPharmacotherapyIndividual DataDrug ResistanceVoriconazole Trough Concentrations	2021	25

Page 1